Breaking News

LakeShore Biopharma’s YSJA Rabies Vaccine Heads to Phase III Trial

Will explore the immunogenicity and safety of a simplified four-dose regimen for the rabies vaccine.

Author Image

By: Charlie Sternberg

Associate Editor

LakeShore Biopharma Co. Ltd, a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, has been granted approval for a Phase III clinical trial by the National Medical Products Administration (NMPA) in China to explore the immunogenicity and safety of a simplified four-dose regimen for its YSJA rabies vaccine.   This simplified immunization schedule has the pot...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters